Arthur E. Reyes
49 works · 678 citations · h-index 8
Top works
- Performance of small-scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: Characterization of separation efficiency and impact of perfusion on product quality
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4
- A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
- A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
- Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection
- Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
- Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies
- 539 POSTER Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb
- 528 POSTER Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information
- Complex formation of anti‐VEGF‐C with VEGF‐C released during blood coagulation resulted in an artifact in its serum pharmacokinetics
- Recombinant DNA Technology and Cell Line Development
- Supplementary Figure 6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- Data from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- Data from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- Supplementary Figure 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- Data from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
- Supplementary Figure 3 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
- Supplementary Table from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development